Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Authors
Keywords
Fabry disease, Enzyme replacement therapy, Recommendations, Delphi procedure
Journal
Orphanet Journal of Rare Diseases
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-03-28
DOI
10.1186/s13023-015-0253-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
- (2015) Linda van der Tol et al. MOLECULAR GENETICS AND METABOLISM
- Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance
- (2014) B.E. Smid et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis
- (2014) Saskia M. Rombach et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Outcomes of patients treated through the Canadian Fabry disease initiative
- (2014) S.M. Sirrs et al. MOLECULAR GENETICS AND METABOLISM
- 2013 ESC guidelines on the management of stable coronary artery disease
- (2013) EUROPEAN HEART JOURNAL
- Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
- (2013) F. Weidemann et al. JOURNAL OF INTERNAL MEDICINE
- A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance
- (2013) L van der Tol et al. JOURNAL OF MEDICAL GENETICS
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
- (2013) Saskia M Rombach et al. Orphanet Journal of Rare Diseases
- Fabry disease in children: agalsidase-beta enzyme replacement therapy
- (2012) L Borgwardt et al. CLINICAL GENETICS
- Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease
- (2012) C. Tondel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
- (2012) Saskia M. Rombach et al. PLoS One
- Safety of agalsidase alfa in patients with Fabry disease under 7 years
- (2010) U Ramaswami et al. ACTA PAEDIATRICA
- Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease
- (2010) Raphael Schiffmann et al. JOURNAL OF PEDIATRICS
- Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy
- (2009) Frank Weidemann et al. CIRCULATION
- Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study
- (2008) S Buechner et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease
- (2008) Bernard Bénichou et al. MOLECULAR GENETICS AND METABOLISM
- Effects of enzyme replacement therapy on the cardiomyopathy of Anderson Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
- (2007) D A Hughes et al. HEART
- Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease
- (2007) J. Edmond Wraith et al. JOURNAL OF PEDIATRICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started